Julien Anract
Overview
Explore the profile of Julien Anract including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pinar U, Sarrazin C, Anract J, Chevrot A, Fassi-Fehri H, Wilisch J, et al.
Fr J Urol
. 2025 Mar;
:102877.
PMID: 40089020
Introduction: Benign prostatic hyperplasia (BPH) is a prevalent condition in ageing men, often resulting in significant lower urinary tract symptoms (LUTS) that impact quality of life. For patients with huge...
2.
Manfredini G, Anract J, Barry Delongchamps N
Fr J Urol
. 2025 Feb;
35(5):102870.
PMID: 39983905
Objective: To evaluate the accuracy of bladder scanners in measuring bladder volume and to compare their precision. Method: MEDLINE and Cochrane databases were searched from January 1, 1990 to December...
3.
Peyrottes A, Baboudjian M, Diamand R, Ducrot Q, Vitard C, Baudewyns A, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39965998
Background And Objective: Patients with Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions are at a high risk of clinically significant prostate cancer (PCa), extracapsular extension, and biochemical recurrence...
4.
Klein C, Anract J, Pinar U, Lacroix X, Mansour R, Robert G, et al.
World J Urol
. 2025 Jan;
43(1):75.
PMID: 39820625
Introduction: This study aimed to evaluate the safety and efficacy of HoLEP in patients aged > 85 years with indwelling catheter (IDC). Methods: We retrospectively analyzed our bicentric HoLEP database...
5.
Barry Delongchamps N, Peltier A, Potiron E, Bladou F, Anract J, Diamand R, et al.
BJUI Compass
. 2025 Jan;
5(12):1307-1313.
PMID: 39744070
Objective: The aim of this study was to assess the precision and safety of targeted microwave ablation (TMA) using organ-based tracking (OBT) fusion, in patients with intermediate risk prostate cancer....
6.
Anract J, Klein C, Pinar U, Roupret M, Barry Delongchamps N, Robert G
Eur Urol Oncol
. 2024 Dec;
8(1):213-214.
PMID: 39709258
No abstract available.
7.
Oderda M, Diamand R, Abou Zahr R, Anract J, Assenmacher G, Barry Delongchamps N, et al.
World J Urol
. 2024 Sep;
42(1):535.
PMID: 39320521
Purpose: To evaluate biopsy-related complications and detection rates of any PCa and clinically significant PCa (csPCa, intended as grade group ≥ 2) between MRI-targeted TP fusion biopsies (TPBx) and TR...
8.
Anract J, Klein C, Pinar U, Roupret M, Barry Delongchamps N, Robert G
Eur Urol Oncol
. 2024 Sep;
8(1):145-151.
PMID: 39256094
Background And Objective: Histopathological examination of surgical specimens for benign prostatic hyperplasia (BPH) can detect incidental prostate cancer (iPCa). The aim of our study was to develop a predictive model...
9.
Mjaess G, Haddad L, Jabbour T, Baudewyns A, Bourgeno H, Lefebvre Y, et al.
Prostate Cancer Prostatic Dis
. 2024 Jul;
28(1):173-179.
PMID: 39048664
Background: Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, identified through multiparametric magnetic resonance imaging (mpMRI), present a clinical challenge due to their equivocal nature in predicting clinically significant...
10.
Diamand R, Guenzel K, Jabbour T, Baudewyns A, Bourgeno H, Lefebvre Y, et al.
World J Urol
. 2024 Jun;
42(1):372.
PMID: 38866949
Purpose: Magnetic resonance imaging (MRI) is a promising tool for risk assessment, potentially reducing the burden of unnecessary prostate biopsies. Risk prediction models that incorporate MRI data have gained attention,...